Abstract
Safety and Efficacy of Long-Term Open-Label Dosing of Subcutaneous (SC) Romiplostim in Pediatric Patients with Immune Thrombocytopenia (ITP)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have